ProKidney Corp.

NASDAQ•PROK

CEO: Dr. Bruce Culleton M.D.

Sector: Healthcare

Industry: Biotechnology

Listing Date: 2021-06-30

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Contact Information

2000 Frontis Plaza Blvd., Suite 250, Winston-Salem, NC, 27103, United States

336-999-7028

www.prokidney.com

Market Cap

$506.65M

P/E (TTM)

-3.4

22.5

Dividend Yield

52W High

$7.13

52W Low

$0.54

52W Range

18%

Rank56Top 81.7%

2.5

F-Score

Modified Piotroski Analysis

Based on 6-year fundamentals

Weak • 2.5 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2020-2025

Financial Dashboard

Q4 2025 Data

Revenue

$225.00K+0.00%

4-Quarter Trend

EPS

-$0.14+0.00%

4-Quarter Trend

FCF

-$38.27M+0.00%

4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Revenue Rises on Leasing Revenue reached $893K in 2025, up $817K, primarily from full year leasing activities recognized.

R&D Spending Decreases R&D expenses fell $13.5M to $114.1M, driven by completed clinical studies and compliance remediation efforts.

Phase 3 Trial Progressing Ongoing PROACT 1 Phase 3 trial confirmed eGFR slope as surrogate endpoint for BLA submission.

Cash Position Maintained Cash, equivalents, and investments total $270.0M, funding operations into mid-2027 based on current plan.

Risk Factors

Need Substantial Future Capital Company incurred net losses since inception; expects substantial future funding required to complete development programs.

Clinical Development Uncertain Outcome Rilparencel development is highly speculative; failure to achieve efficacy or regulatory approval significantly harms prospects.

Complex Manufacturing Process Risks Manufacturing autologous cell therapy is complex; supply chain disruptions or quality failures could delay commercialization.

Intense Competition From Biologics Faces strong competition from established players and new GLP-1 RA drugs impacting potential market size.

Outlook

Continue Phase 3 Enrollment Maintain ongoing dialogue with FDA; continue enrollment for PROACT 1 trial targeting approximately 470 patients.

Anticipate Topline Data 2027 Expect topline readout for surrogate endpoint (eGFR slope) in second quarter of 2027.

Refine Internal Manufacturing Intends to improve bioprocess development to reduce commercial manufacturing costs assuming necessary regulatory approvals.

Discover Additional Product Candidates Team will investigate additional disease pathways utilizing cell therapy approach to generate new product candidates.

Peer Comparison

Revenue (TTM)

ANAB

$232.39M

+107.7%

PHAT

$204.89M

+150.3%

MRVI

$204.73M

-15.3%

Gross Margin (Latest Quarter)

NBTX

100.0%

+0.0pp

KURA

98.6%

+0.0pp

PHAT

79.4%

+1.9pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
TNGX	$2.96B	-34.2	-41.5%	7.5%
ANAB	$2.70B	-67.1	442.9%	4.1%
NBTX	$2.52B	-87.3	31.2%	140.7%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

-0.7%

Flat Growth

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

Cash Flow Needs Attention

Deep Research

Next earnings:Aug 6, 2026

EPS:-$0.14

Revenue:$110.25K

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data